Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with dyslipidemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

NCT02250105

Hypertriglyceridemia

COMPLETED PHASE2

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

NCT03051100

Hypercholesterolemia

COMPLETED PHASE2

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

NCT04055168

Dyslipidemia

TERMINATED PHASE1

Lipid Efficacy Study (0524B-022)(COMPLETED)

NCT00269217

Primary Hypercholesterolemia Mixed Hyperlipidemia

COMPLETED PHASE3

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

NCT03381287

Hypercholesterolemia

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, multi-center, randomized, double-blinded, controlled clinical trial. The study will compare two arms: ARI-3037MO 3 g BID vs. placebo.

Subjects who sign informed consent will be enrolled and will undergo all Visit 1 assessments. Following evaluation of Visit 1 laboratory assays, eligible subjects will receive a phone call (Visit 2) during which they will be instructed to begin the lifestyle modification and enter a 4- to 6-week lead-in period (6-week wash-out period for subjects to wash out of non-statin lipid-lowering therapy \[subjects may remain on statins during this period\], 4 weeks for subjects receiving statins only or not receiving any lipid-lowering therapy), followed by a qualifying fasting LDL-C measurement at Visit 3. After the lead-in period, if the LDL-C level at Visit 3 is not ≥ 100 mg/dL, an additional week will be allowed for another qualifying measurement at a subsequent visit (Visit 3.1). If performed, the LDL-C level at Visit 3.1 must be ≥ 100 mg/dL in order for the subject to continue participation in the study. Qualifying subjects will be randomized in a 1:1 manner at Visit 4 to one of two arms of the double-blind, 24-week efficacy and safety assessment phase. Randomization will be stratified by background statin therapy status at Visit 1 (yes/no). Baseline lipid levels will be defined as lipid levels at Visit 4. End-of-study lipid levels will be defined as the lipid levels at Visit 7 (Week 24).

A final closeout and safety assessment visit will be held at 26 weeks post randomization (Visit 8).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

ARI-3037MO (niacin analog) 3g bid for 24 wks

Group Type ACTIVE_COMPARATOR

ARI-3037MO

Intervention Type DRUG

Lipid lowering treatment Statins

Placebo

Matching Placebo 3g bid for 24 wks

Group Type PLACEBO_COMPARATOR

ARI-3037MO

Intervention Type DRUG

Lipid lowering treatment Statins

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARI-3037MO

Lipid lowering treatment Statins

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years at screening.
2. Women of childbearing potential, must agree to use 2 medically accepted, effective methods of birth control. Females who are postmenopausal must have been postmenopausal for \> 1 year if they wish not to use contraceptives. If postmenopausal status is questionable, the subject's follicle-stimulating hormone level must be elevated and consistent with postmenopausal levels (i.e., \> 40 IU/L); otherwise these subjects must agree to use contraceptives listed above.
3. Male subjects with sexual partners of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening through 12 weeks after last dose of study drug to prevent pregnancy in a partner.
4. Female subjects of childbearing potential (including females with questionable postmenopausal status) must have a negative pregnancy test prior to dosing.
5. LDL-C level: ≥ 100 mg/dL.
6. Triglycerides (TG) ≤ 300 mg/dL.
7. High-density lipoprotein cholesterol (HDL-C) level \< 45 mg/dL in men and \< 50 mg/dL in women.
8. Subject understands the trial requirements and the treatment procedures, is willing to comply with all protocol-required follow-up evaluation and provides written informed consent
9. Subjects will be managed according to current standard of care. Subjects taking statin therapy will remain on their statin background therapy and must be on a stable dose, defined as no changes in the dose of statin in the 3 months prior to screening, and must be willing and able to remain on that dose for the duration of the study.

Exclusion Criteria

1. Subjects treated with any statin at its maximally approved dose will be excluded from the study.
2. Body mass index (BMI) \> 45 kg/m2.
3. Weight change ≥ 3 kg during the lead-in period.
4. Uncontrolled diabetes, defined as glycosylated hemoglobin (HbA1C) \> 9.5%.
5. Contraindication to niacin treatment (prior flushing is not regarded as a contraindication to niacin treatment).
6. History of stroke, myocardial infarction, life-threatening arrhythmia, or having had coronary vascularization within 6 months before screening.
7. Thyroid-stimulating hormone ≥ 1.5 times the upper limit of normal (ULN).
8. Clinical evidence of hypothyroidism or thyroid hormonal therapy that has not been stable for ≥ 6 weeks before screening.
9. Creatine kinase concentration ≥ 3 times the ULN.
10. Known, active liver disease, including but not limited to

1. Confirmed alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase ≥ 2 times the ULN, or bilirubin ≥ 1.5 times the ULN.
2. Hepatitis C (anti-hepatitis C virus immunoglobulin G +).
3. Hepatitis B (hepatitis B surface antigen +, anti-hepatitis B core antigen immunoglobulin M +).
11. Blood donation of ≥ 1 pint (0.5 L) within 30 days before screening or plasma donation within 7 days before screening.
12. Known nephrotic syndrome or ≥ 3 g/day proteinuria.
13. Past organ transplant or on a waiting list for an organ transplant.
14. Subject is currently receiving chemotherapy; or has received chemotherapy within the 30 days prior to screening; or is scheduled to receive chemotherapy during the course of the study.
15. Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months.
16. Problems with substance abuse, which, in the opinion of the Investigator, might affect study compliance.
17. Planned procedure that may cause non-compliance with the protocol or confound data interpretation.
18. Participation in another investigational drug trial in the past 30 days or current participation in a device trial that has not reached its primary endpoint.
19. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study or within 12 weeks after last dose of study drug.
20. Estimated glomerular filtration rate \< 60 mL/min/1.73 m2. -

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catalina Reserch Institute, LLC

Chino, California, United States

Site Status

S&W Clinical Reserch

Fort Lauderdale, Florida, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonvile, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Sestron Clinical Research 833 Campbell Hill Street Suite 230

Marietta, Georgia, United States

Site Status

Midwest Institute for Clinical Research

Indianapolis, Indiana, United States

Site Status

Louisville Metabolic and Atherosclerosis Research Center

Louisville, Kentucky, United States

Site Status